Dolby Laboratories (DLB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Dolby Laboratories stock (DLB) is currently trading at $58.87. Dolby Laboratories PE ratio is 23.74. Dolby Laboratories PS ratio (Price-to-Sales) is 4.18. Analyst consensus price target for DLB is $81.00. WallStSmart rates DLB as Underperform.
- DLB PE ratio analysis and historical PE chart
- DLB PS ratio (Price-to-Sales) history and trend
- DLB intrinsic value — DCF, Graham Number, EPV models
- DLB stock price prediction 2025 2026 2027 2028 2029 2030
- DLB fair value vs current price
- DLB insider transactions and insider buying
- Is DLB undervalued or overvalued?
- Dolby Laboratories financial analysis — revenue, earnings, cash flow
- DLB Piotroski F-Score and Altman Z-Score
- DLB analyst price target and Smart Rating
Dolby Laboratories
📊 No data available
Try selecting a different time range
DLB Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Dolby Laboratories (DLB)
DLB trades 311% above its Graham fair value of $16.80, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Dolby Laboratories (DLB) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, profit margin, institutional own.. Concerns around return on equity and revenue growth. Mixed signals suggest waiting for clearer direction before acting.
Dolby Laboratories (DLB) Key Strengths (4)
98.95% of shares held by major funds and institutions
Strong operational efficiency: $21 kept per $100 revenue
Strong profitability: $18 kept per $100 revenue
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Dolby Laboratories (DLB) Areas to Watch (6)
Revenue declining -2.90%, a shrinking business
Earnings declining -21.40%, profits shrinking
Low profitability relative to shareholder equity
Paying a premium for growth, expensive relative to earnings expansion
Premium valuation at 4.2x annual revenue
Fairly priced relative to book value
Dolby Laboratories (DLB) Detailed Analysis Report
Overall Assessment
This company scores 48/100 in our Smart Analysis, earning a D+ grade. Out of 10 metrics analyzed, 4 register as strengths (avg 8.3/10) while 6 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Operating Margin, Profit Margin. Profitability is solid with Operating Margin at 20.90%, Profit Margin at 18.00%.
The Bear Case
The primary concerns are Revenue Growth, EPS Growth, Return on Equity. Some valuation metrics including PEG Ratio (2.08), Price/Sales (4.18), Price/Book (2.22) suggest expensive pricing. Growth concerns include Revenue Growth at -2.90%, EPS Growth at -21.40%, which may limit upside. Profitability pressure is visible in Return on Equity at 9.46%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 9.46% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -2.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Revenue Growth and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DLB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DLB's Price-to-Sales ratio of 4.18x trades 24% below its historical average of 5.53x (70th percentile). The current valuation is 91% below its historical high of 45.63x set in Nov 2014, and 139% above its historical low of 1.75x in Sep 2011. Over the past 12 months, the PS ratio has compressed from ~4.8x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Dolby Laboratories (DLB) · INDUSTRIALS › SPECIALTY BUSINESS SERVICES
The Big Picture
Dolby Laboratories faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 1.3B with 290% decline year-over-year. Profit margins of 18.0% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 946.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 49M in free cash flow and 55M in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 290% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Sector dynamics: monitor SPECIALTY BUSINESS SERVICES industry trends, competitive moves, and regulatory changes that could impact Dolby Laboratories.
Bottom Line
Dolby Laboratories faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(22 last 3 months)
| Insider | Type | Shares |
|---|---|---|
REVANKAR, SHRIRAM SVP, Advanced Technology Group | Sell | -3,000 |
| Insider | Type | Shares |
|---|---|---|
COULING, JOHN D SVP, Entertainment | Sell | -6,667 |
Data sourced from SEC Form 4 filings
Last updated: 8:28:24 AM
About Dolby Laboratories(DLB)
NYSE
INDUSTRIALS
SPECIALTY BUSINESS SERVICES
USA
Dolby Laboratories, Inc. creates imaging and audio technologies that transform entertainment and communications in the theater, home, work, and mobile devices. The company is headquartered in San Francisco, California.